Ibuprofen
- CAS No.
- 15687-27-1
- Chemical Name:
- Ibuprofen
- Synonyms
- buluofen;Advil;Buprofen;rufen;Dolgit;Nurofen;2-(p-Isobutylphenyl)propionic acid;[A-METHYL-4-ISOBUTYL]PHENYLACETIC ACID;ALPHA-METHYL-4-(ISOBUTYL)PHENYLACETIC ACID;[2R,(-)]-2-[4-(2-Methylpropyl)phenyl]propanoic acid
- CBNumber:
- CB4336930
- Molecular Formula:
- C13H18O2
- Molecular Weight:
- 206.28
- MOL File:
- 15687-27-1.mol
- MSDS File:
- SDS
- Modify Date:
- 2025/3/27 6:45:46
| Melting point | 77-78 °C |
|---|---|
| alpha | [α]D20 -1～+1°(c=1,C2H5OH) |
| Boiling point | 157 °C (4 mmHg) |
| Density | 1.0364 (rough estimate) |
| refractive index | 1.5500 (estimate) |
| Flash point | 9℃ |
| storage temp. | 2-8°C |
| solubility | Practically insoluble in water, freely soluble in acetone, in methanol and in methylene chloride. It dissolves in dilute solutions of alkali hydroxides and carbonates. |
| pka | pKa 4.45± 0.04(H2O,t = 25±0.5,I=0.15(KCl))(Approximate) |
| form | Crystalline Powder |
| color | white to off-white |
| biological source | synthetic (organic) |
| Water Solubility | insoluble |
| Merck | 14,4881 |
| BCS Class | 2 |
| Stability | Stable. Combustible. Incompatible with strong oxidizing agents. |
| InChIKey | HEFNNWSXXWATRW-UHFFFAOYSA-N |
| LogP | 3.970 |
| CAS DataBase Reference | 15687-27-1(CAS DataBase Reference) |
| NIST Chemistry Reference | Ibuprofen(15687-27-1) |
| EPA Substance Registry System | Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)- (15687-27-1) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Warning | |||||||||
| Hazard statements | H302-H319-H335 | |||||||||
| Precautionary statements | P261-P264-P270-P271-P301+P312-P305+P351+P338 | |||||||||
| Hazard Codes | Xn | |||||||||
| Risk Statements | 22-63-51/53-39/23/24/25-23/24/25-11 | |||||||||
| Safety Statements | 36-61-36/37-45-16-7 | |||||||||
| HS Code | 29163920 | |||||||||
| Hazardous Substances Data | 15687-27-1(Hazardous Substances Data) | |||||||||
| Toxicity | LD50 in male mice, rats (mg/kg): 495, 626 i.p.; 1255, 1050 orally (Orzalesi) | |||||||||
| NFPA 704 |
|
Ibuprofen price More Price(12)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | I4883 | Ibuprofen ≥98% (GC) | 15687-27-1 | 1G | ₹5336.73 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PHR1004 | Ibuprofen Pharmaceutical Secondary Standard; Certified Reference Material | 15687-27-1 | 1G | ₹8356.9 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | I4883 | Ibuprofen ≥98% (GC) | 15687-27-1 | 5G | ₹15479.75 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | I110 | Ibuprofen | 15687-27-1 | 1G | ₹3247.5 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | I110 | Ibuprofen | 15687-27-1 | 5G | ₹12935.88 | 2022-06-14 | Buy |
Ibuprofen Chemical Properties,Uses,Production
Chemical Properties
Colourless, Crystalline Solid
History
Ibuprofen was developed while searching for an alternative pain reliever to aspirin in the 1950s. It and related compounds were synthesized in 1961 by Stewart Adams, John Nicholson, and Colin Burrows who were working for the Boots Pure Drug Company in Great Britain. Adams and Nicholson filed for a British patent on ibuprofen in 1962 and obtained the patent in 1964; subsequent patents were obtained in the United States. The patent of Adams and Nicholson was for the invention of phenylalkane derivatives of the form shown in Figure 49.1, where R1 could be various alkyl groups, R2 was hydrogen or methyl, and X was COOH or COOR, with R being alkyl or aminoalkyl groups. The first clinical trials for ibuprofen were started in 1966. Ibuprofen was introduced under the trade name Brufen in 1969 in Great Britain. It was introduced in the United States in 1974. Ibuprofen was initially off ered by prescription, but it became available in over-the-counter medications in the 1980s.
Uses
A common goal in the development of pain and inflammation medicines has been the creation of compounds that have the ability to treat inflammation, fever, and pain without disrupting other physiological functions. General pain relievers, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. A medication's specificaction toward COX-1 versus COX-2 determines the potential for adverse side effects. Medications with greater specificity toward COX-1 will have greater potential for producing adverse side effects. By deactivating COX-1, nonselective pain relievers increase the chance of undesirable side effects, especially digestive problems such as stomach ulcers and gastrointestinal bleeding. COX-2 inhibitors, such as Vioxx and Celebrex, selectively deactivate COX-2 and do not aff ect COX-1 at prescribed dosages. COX-2 inhibitors are widely prescribed for arthritis and pain relief. In 2004, the Food and Drug Administration (FDA) announced that an increased risk of heart attack and stroke was associated with certain COX-2 inhibitors. This led to warning labels and voluntary removal of products from the market by drug producers; for example, Merck took Vioxx off the market in 2004. Although ibuprofen inhibits both COX-1 and COX-2, it has several times the specificity toward COX-2 compared to aspirin, producing fewer gastrointestinal side effects.
Indications
Ibuprofen (Advil, Motrin) is used as an analgesic and antipyretic as well as a treatment for rheumatoid arthritis and degenerative joint disease. The most frequently observed side effects are nausea, heartburn, epigastric pain, rash, and dizziness. Incidence of GI side effects is lower than with indomethacin.Visual changes and cross-sensitivity to aspirin have been reported. Ibuprofen inhibits COX-1 and COX-2 about equally. It decreases platelet aggregation, but the duration is shorter and the effect quantitatively lower than with aspirin. Ibuprofen prolongs bleeding times toward high normal value and should be used with caution in patients who have coagulation deficits or are receiving anticoagulant therapy.
Definition
ChEBI: A monocarboxylic acid that is propionic acid in which one of the hydrogens at position 2 is substituted by a 4-(2-methylpropyl)phenyl group.
World Health Organization (WHO)
Ibuprofen, a non-steroidal anti-inflammatory agent, was introduced in 1969. It was approved for sale without prescription in packages containing no more than 400 mg, in the United Kingdom in 1983. This action was followed by the USA, Canada and several European countries. Since this time reports of suspected adverse effects have increased. Most of these relate to gastrointestinal disturbances, hypersensitivity reactions but aseptic meningitis, skin rashes and renal damage have been recorded.
General Description
Ibuprofen, 2-(4-isobutylphenyl)propionic acid (Motrin,Advil, Nuprin), was introduced into clinical practice followingextensive clinical trials. It appears to have comparableefficacy to aspirin in the treatment of RA, but with a lowerincidence of side effects. It has also been approved for usein the treatment of primary dysmenorrhea, which is thoughtto be caused by an excessive concentration of PGs and endoperoxides. However, a recent study indicates that concurrentuse of ibuprofen and aspirin may actually interferewith the cardioprotective effects of aspirin, at least in patientswith established cardiovascular disease. This is becauseibuprofen can reversibly bind to the platelet COX-1isozymes, thereby blocking aspirin’s ability to inhibit TXA2synthesis in platelets.
Pharmacokinetics
Ibuprofen is rapidly absorbed on oral administration, with peak plasma levels being generally attained within 2 hours and a duration of action of less than 6 hours. As with most of these acidic NSAIDs, ibuprofen (pKa = 4.4) is extensively bound to plasma proteins (99%) and will interact with other acidic drugs that are protein bound.
Clinical Use
Ibuprofen is indicated for the relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis, the relief of mild to moderate pain, the reduction of fever, and the treatment of dysmenorrhea.
Environmental Fate
Ibuprofen has a high water solubility and low volatility, which suggest a high mobility in the aquatic environment. This makes it a commonly detected chemical of the pharmaceutical and personal care products (PPCPs) in the environment. It is not as persistent, however, as many other chemicals. Ibuprofen undergoes photodegradation with exposure to direct and indirect sunlight, although degradation products can have effects on aquatic environments.
Metabolism
Metabolism occurs rapidly, and the drug is nearly completely excreted in the urine as unchanged drug and oxidative metabolites within 24 hours following administration. Metabolism by CYP2C9 (90%) and CYP2C19 (10%) involves primarily ω-, and ω1-, and ω2-oxidation of the p-isobutyl side chain, followed by alcohol oxidation of the primary alcohol resulting from ω–oxidation to the corresponding carboxylic acid. All metabolites are inactive. When ibuprofen is administered as the individual enantiomers, the major metabolite isolated is the S-(+)-enantiomer whatever the configuration of the starting enantiomer. Interestingly, the R-(–)-enantiomer is inverted to the S-(+)-enantiomer in vivo via an acetyl–coenzyme A intermediate, accounting for the observation that the two enantiomers are bioequivalent in vivo. This is a metabolic phenomenon that also has been observed for other arylpropionic acids, such as ketoprofen, benoxaprofen, fenoprofen, and naproxen.
Ibuprofen Preparation Products And Raw materials
Raw materials
1of3
chevron_rightPreparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| ANWITA APIS | +919000311012 | Hyderabad, India | 195 | 58 | Inquiry |
| Frolic Pharmachem | +919711094561 | Himachal Pradesh, India | 94 | 58 | Inquiry |
| Reenold Enterprises | +91-8208173540 +91-8208173540 | Maharashtra, India | 28 | 58 | Inquiry |
| Cefa-Cilinas Biotics Pvt Ltd | +91-7875033155 +91-8080701561 | Maharashtra, India | 121 | 58 | Inquiry |
| HRV Global Life Sciences | +91-9820219686 +91-9820219686 | Telangana, India | 379 | 58 | Inquiry |
| SMS Pharmaceuticals Ltd | +91-8179850881 +91-9100092121 | Telangana, India | 22 | 58 | Inquiry |
| Solara Active Pharma Sciences Ltd | +91-8046632100 +91-7075706520 | Bangalore, India | 65 | 58 | Inquiry |
| Rivashaa Agrotech Biopharma Pvt. Ltd. | +91-26463395 +91-7926462688 | Gujarat, India | 1615 | 58 | Inquiry |
| Humble Healthcare Limited | +91-9720093000 +91-8006400378 | Uttar Pradesh, India | 140 | 58 | Inquiry |
| Magma Industries Ltd | +91-1144467935 +91-7302894888 | Uttar Pradesh, India | 9 | 58 | Inquiry |
Related articles
- Classical Synthesis and Recent Synthetic Advances in Ibuprofen
- Ibuprofen was developed in the 1960s and was valued at around 300 million US dollars in 2020. This article will introduce its ....
- Jul 31，2024
- Is it dangerous to overdose on Ibuprofen?
- If it's abused and taken in large quantities in a short period of time, it can cause water buildup in the brain or swelling of....
- Mar 11，2024
- What's the Difference between Ibuprofen and Excedrin? Can We Take Them Together?
- Be careful when you take the anti-inflammatory drugs, both aspirin and ibuprofen are classified as nonsteroidal anti-inflammat....
- Mar 11，2024
15687-27-1(Ibuprofen)Related Search:
1of4
chevron_right